Novel approaches to treatingClostridium difficile-associated colitis

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection

(2015) Thomas Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difficile

(2015) Mohammed Zahidul Alam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prevention of Clostridium difficile Infection With Probiotics

(2015) Charlesnika T. Evans et al.   CLINICAL INFECTIOUS DISEASES

Investigational new treatments for Clostridium difficile infection

(2015) Mattias E. Ivarsson et al.   DRUG DISCOVERY TODAY

Tu2054 SYN-004, a Clinical Stage Oral Beta-Lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-Mediated Damage in Humanized Pigs

(2015) Sheila Connelly et al.   GASTROENTEROLOGY

The Prospect for Vaccines to Prevent Clostridium difficile Infection

(2015) Chandrabali Ghose et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Diagnosis and Treatment ofClostridium difficilein Adults

(2015) Natasha Bagdasarian et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Administration of Spores of NontoxigenicClostridium difficileStrain M3 for Prevention of RecurrentC difficileInfection

(2015) Dale N. Gerding et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Burden of Clostridium difficile Infection in the United States

(2015) Fernanda C. Lessa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clostridium difficile Infection

(2015) Daniel A. Leffler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mo1116 The Efficacy and Safety of Rifaximin vs. Vancomycin in the Treatment of Mild to Moderate C. difficile Infection: A Randomized Double-Blind Active Comparator Trial

(2015) Darrell S. Pardi et al.   GASTROENTEROLOGY

The Evolution of Urban C. difficile Infection (CDI): CDI in 2009–2011 Is Less Severe and has Better Outcomes Than CDI in 2006–2008

(2014) Paul Feuerstadt et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Fidaxomicin Inhibits Clostridium difficile Toxin A-Mediated Enteritis in the Mouse Ileum

(2014) Hon Wai Koon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis

(2014) Gauree G. Konijeti et al.   CLINICAL INFECTIOUS DISEASES

Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials

(2014) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

Hospital-Acquired Clostridium difficile Infections

(2014) Eric T. Lofgren et al.   EPIDEMIOLOGY

Targeted adsorption of molecules in the colon with the novel adsorbent-based Medicinal Product, DAV132: A proof of concept study in healthy subjects

(2014) Jean de Gunzburg et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Multistate Point-Prevalence Survey of Health Care–Associated Infections

(2014) Shelley S. Magill et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commercially available probiotic drinks containingLactobacillus caseiDN-114001 reduce antibiotic-associated diarrhea

(2014) Christoph G Dietrich   WORLD JOURNAL OF GASTROENTEROLOGY

Guidelines for Diagnosis, Treatment and Prevention of Clostridium difficile Infections

(2013) Christina M Surawicz et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Investigations of the Mode of Action and Resistance Development of Cadazolid, a New Antibiotic for Treatment of Clostridium difficile Infections

(2013) Hans H. Locher et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Human Monoclonal Antibodies against Clostridium difficile Toxins A and B Inhibit Inflammatory and Histologic Responses to the Toxins in Human Colon and Peripheral Blood Monocytes

(2013) Hon Wai Koon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroandIn VivoAntibacterial Evaluation of Cadazolid, a New Antibiotic for Treatment of Clostridium difficile Infections

(2013) Hans H. Locher et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Is Fidaxomicin Worth the Cost? An Economic Analysis

(2013) Sarah M. Bartsch et al.   CLINICAL INFECTIOUS DISEASES

The Epidemiology of Clostridium difficile Infection in Children: A Population-Based Study

(2013) Sahil Khanna et al.   CLINICAL INFECTIOUS DISEASES

European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection

(2013) S.B. Debast et al.   CLINICAL MICROBIOLOGY AND INFECTION

Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection

(2013) Andrew D. Cox et al.   GLYCOCONJUGATE JOURNAL

Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile

(2013) Els van Nood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers

(2013) Michael S.M. Brouwer et al.   Nature Communications

Clostridium difficile infection in the twenty-first century

(2013) Chandrabali Ghose   Emerging Microbes & Infections

Clostridium difficile infection: management strategies for a difficult disease

(2013) Sahil Khanna et al.   Therapeutic Advances in Gastroenterology

Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection

(2012) Matthew J Hamilton et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

In VitroandIn VivoCharacterization of CB-183,315, a Novel Lipopeptide Antibiotic for Treatment of Clostridium difficile

(2012) Carmela T. M. Mascio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of an Oral Suspension of VP20621, Spores of Nontoxigenic Clostridium difficile Strain M3, in Healthy Subjects

(2012) Stephen A. Villano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Can we identify patients at high risk of recurrent Clostridium difficile infection?

(2012) C.P. Kelly   CLINICAL MICROBIOLOGY AND INFECTION

Treating recurrent C. difficile infection—the challenge continues

(2012) Christina M. Surawicz   Nature Reviews Gastroenterology & Hepatology

Clostridium difficile: Development of a novel candidate vaccine

(2012) Ginamarie Foglia et al.   VACCINE

Diverting Loop Ileostomy and Colonic Lavage

(2011) Matthew D. Neal et al.   ANNALS OF SURGERY

Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection

(2011) Ethan Gough et al.   CLINICAL INFECTIOUS DISEASES

Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community Hospitals

(2011) Becky A. Miller et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders

(2011) Theodoros Kelesidis et al.   Therapeutic Advances in Gastroenterology

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

(2010) Stuart H. Cohen et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread

(2010) Archie CA Clements et al.   LANCET INFECTIOUS DISEASES

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

(2010) G. W. Tannock et al.   MICROBIOLOGY-SGM

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: anti-inflammatory mechanisms of action ofSaccharomyces boulardii

(2009) C. POTHOULAKIS   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study

(2009) Daniel M. Musher et al.   CLINICAL INFECTIOUS DISEASES

Treatment of Clostridium difficile-Associated Disease

(2009) Daniel A. Leffler et al.   GASTROENTEROLOGY

Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile-Associated Diarrhea and Prevention of Disease Recurrence in Hamsters

(2008) E. Kokkotou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review

(2008) Michael Gerber et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection

(2008) Mary Y. Hu et al.   GASTROENTEROLOGY

Meta-analysis to assess risk factors for recurrent Clostridium difficile infection

(2008) K.W. Garey et al.   JOURNAL OF HOSPITAL INFECTION

Clostridium difficile— More Difficult Than Ever

(2008) Ciarán P. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

INCREASE IN CLOSTRIDIUM DIFFICILE-RELATED HOSPITALIZATIONS AMONG INFANTS IN THE UNITED STATES, 2000–2005

(2008) Marya D. Zilberberg et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Epidemiological Features of Clostridium difficile-Associated Disease Among Inpatients at Children's Hospitals in the United States, 2001-2006

(2008) J. Kim et al.   PEDIATRICS